What is Vyriad?
Vyriad is a Rochester, Minnesota-based biotechnology company focused on the development of virus-based therapeutics. By leveraging proprietary platforms derived from VSV, measles, and picornaviruses, the company programs viruses to selectively infect and destroy cancer cells. This mechanism of action is intended to ignite the patient's own immune system to complete tumor destruction and prevent recurrence. The company maintains a high-authority market position through its strategic collaboration with Regeneron Pharmaceuticals, which integrates Vyriad's oncolytic virus technology with advanced antibody discovery and PD-1 inhibitor therapies. Keywords: oncolytic virus, cancer immunotherapy, clinical-stage biotech, VSV platform, oncology research, biotechnology investment, therapeutic innovation, cancer treatment.
How much funding has Vyriad raised?
Vyriad has raised a total of $95M across 2 funding rounds:
Series A
$10M
Series B
$85M
Series A (2017): $10M, investors not publicly disclosed
Series B (2025): $85M led by Regeneron, Mr. Harry Stine, Mirae Asset, and Mayo Clinic
Key Investors in Vyriad
Regeneron
Regeneron is a biotechnology company that discovers, develops, and commercializes innovative medicines for serious diseases. The company focuses on using advanced science and proprietary technologies to create life-changing treatments for conditions such as cancer, eye diseases, inflammatory disorders, and rare diseases.
Mayo Clinic
Mayo Clinic is a nonprofit global healthcare organization specializing in integrated clinical practice, education, and medical research. The institution is recognized for its multidisciplinary approach to patient care and its significant contributions to medical innovation.
Mr. Harry Stine
An individual investor participating in the funding round to support the advancement of clinical-stage oncology therapeutics.
What's next for Vyriad?
With the successful closure of this major strategic investment, Vyriad is well-positioned to scale its clinical operations and deepen its research capabilities. The company's roadmap involves the continued evaluation of its lead VSV-derived platform across multiple cancer indications, supported by the technical and financial backing of its strategic partners. Future milestones will likely focus on data readouts from ongoing Phase 1-2 trials, which are critical for validating the efficacy of its virus-based approach in human subjects. Furthermore, the partnership with Regeneron provides a clear pathway for the potential commercialization of combination therapies, potentially transforming the standard of care for patients with significant unmet medical needs. The firm remains focused on advancing its pipeline while maintaining its commitment to rigorous scientific research and clinical excellence.
See full Vyriad company page
